Gilead Sciences Inc. (GILD) says late-stage results for HIV drug combination are similar to standard of care

0
326

Gilead Sciences says late-stage results for HIV drug combination are similar to standard of care

Gilead Sciences Inc. GILD, +0.46% said early Monday that its HIV combination treatment had similar safety and efficacy results in two late-stage clinical trials to the standard of care. The data, along with two other late-stage clinical trials, are the basis of Gilead’s U.S. and European regulatory submissions, the company said. The combination of the drugs bictegravir and emtricitabine/tenofovir alafenamide is intended for patients who are new to treatment. One of the phase 3 studies, which enrolled 629 patients, found that 92.4% of patients on the BIC/FTC/TAF combination treatment achieved the primary endpoint at week 48, compared with 93% of patients achieving the primary endpoint on the other regimen.

LEAVE A REPLY

Please enter your comment!
Please enter your name here